• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

厄他培南。

Ertapenem.

机构信息

Akron Children's Hospital - Pediatric Infectious Diseases, One Perkins Square, Akron, OH 44333, USA.

出版信息

Expert Opin Pharmacother. 2010 Mar;11(4):669-72. doi: 10.1517/14656561003631397.

DOI:10.1517/14656561003631397
PMID:20163277
Abstract

IMPORTANCE OF THE FIELD

Given their broad-spectrum and safety, carbapenems are a widely used class of antibiotics, especially in the treatment of hospital-acquired infections including infections due to multidrug-resistant organisms. Ertapenem is a unique member of this class, with a narrower spectrum that lacks reliable activity against Pseudomonas and Enterococcus. Given its spectrum and half-life of 4 h it is better suited to use in community-acquired infections and it is particularly well positioned for use in the outpatient setting.

AREAS COVERED IN THIS REVIEW

Chemistry, mechanism of action, pharmacokinetics/pharmacodynamics, safety and indications for use will be covered in this review. Similar to other beta-lactams, the carbapenems inhibit cell wall synthesis by binding to and inhibiting penicillin-binding proteins. Their resistance to beta-lactamases including AmpC and extended-spectrum beta-lactamases enhances their usefulness. Similar to other beta-lactams, ertapenem exhibits time-dependent killing. Given this profile, ertapenem has been found to be useful in intra-abdominal infections, acute pelvic infections, complicated skin and skin structure infections, community-acquired pneumonia and complicated urinary tract infections.

WHAT THE READER WILL GAIN

This review will enable the reader to understand differences between the different carbapenems, especially with regard to ertapenem. Once an understanding is gained with regard to pharmacology and microbiology, the reader will be positioned to understand better those circumstances in which use of ertapenem should be considered.

TAKE HOME MESSAGE

Substantial differences between the carbapenems exist. Ertapenem has unique characteristics that may make it useful in specific clinical circumstances that are detailed in this review.

摘要

重要性领域

鉴于其广谱性和安全性,碳青霉烯类抗生素是一种广泛使用的抗生素类别,特别是在治疗医院获得性感染方面,包括多药耐药菌引起的感染。厄他培南是该类药物中的一个独特成员,其谱较窄,对铜绿假单胞菌和肠球菌缺乏可靠的活性。鉴于其谱和 4 小时的半衰期,它更适合用于社区获得性感染,特别适合在门诊环境中使用。

涵盖的领域

本综述将涵盖化学、作用机制、药代动力学/药效学、安全性和适应证。与其他β-内酰胺类药物一样,碳青霉烯类通过与青霉素结合蛋白结合并抑制其活性来抑制细胞壁合成。它们对包括 AmpC 和超广谱β-内酰胺酶在内的β-内酰胺酶的耐药性增强了它们的用途。与其他β-内酰胺类药物一样,厄他培南表现出时间依赖性杀菌作用。鉴于这种特性,厄他培南已被证明可用于治疗腹腔内感染、急性盆腔感染、复杂皮肤和皮肤结构感染、社区获得性肺炎和复杂尿路感染。

读者将获得的收益

本综述将使读者能够理解不同碳青霉烯类药物之间的差异,特别是厄他培南。一旦对药理学和微生物学有了了解,读者将能够更好地理解在哪些情况下应考虑使用厄他培南。

重要信息

碳青霉烯类药物之间存在显著差异。厄他培南具有独特的特性,使其在本综述中详细描述的某些特定临床情况下可能有用。

相似文献

1
Ertapenem.厄他培南。
Expert Opin Pharmacother. 2010 Mar;11(4):669-72. doi: 10.1517/14656561003631397.
2
Ertapenem.厄他培南
Kathmandu Univ Med J (KUMJ). 2009 Oct-Dec;7(28):454-60.
3
In vitro activity of ertapenem: review of recent studies.厄他培南的体外活性:近期研究综述
J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii11-21. doi: 10.1093/jac/dkh204.
4
Properties and potential of ertapenem.厄他培南的特性与潜力。
J Antimicrob Chemother. 2003 Sep;52(3):331-44. doi: 10.1093/jac/dkg375. Epub 2003 Aug 13.
5
Carbapenems: a potent class of antibiotics.碳青霉烯类:一类强效抗生素。
Expert Opin Pharmacother. 2008 Jan;9(1):23-37. doi: 10.1517/14656566.9.1.23.
6
Comparative review of the carbapenems.碳青霉烯类药物的比较性综述。
Drugs. 2007;67(7):1027-52. doi: 10.2165/00003495-200767070-00006.
7
Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections.厄他培南用于治疗产超广谱β-内酰胺酶革兰阴性菌感染。
Int J Antimicrob Agents. 2007 Oct;30(4):356-9. doi: 10.1016/j.ijantimicag.2007.05.016. Epub 2007 Jul 13.
8
Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.厄他培南的药代动力学和药效学:临床医生概述
J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii23-8. doi: 10.1093/jac/dkh205.
9
[Available carbapenems: Properties and differences].[可用碳青霉烯类药物:特性与差异]
Enferm Infecc Microbiol Clin. 2010 Sep;28 Suppl 2:53-64. doi: 10.1016/S0213-005X(10)70031-8.
10
Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.厄他培南:一种具有独特抗菌和药理特性的1类碳青霉烯类药物。
J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii7-9. doi: 10.1093/jac/dkh203.

引用本文的文献

1
A disproportionality analysis of adverse events associated with ertapenem using the FAERS database from 2004 to 2024.使用2004年至2024年的FAERS数据库对与厄他培南相关的不良事件进行不成比例分析。
Sci Rep. 2025 May 19;15(1):17301. doi: 10.1038/s41598-025-02359-3.
2
Prevalence and characteristics of ertapenem-mono-resistant isolates among carbapenem-resistant Enterobacterales in China.中国碳青霉烯类耐药肠杆菌科中厄他培南单耐药分离株的流行情况和特征。
Emerg Microbes Infect. 2024 Dec;13(1):2332658. doi: 10.1080/22221751.2024.2332658. Epub 2024 Apr 3.
3
The effect of clinically relevant beta-lactam, aminoglycoside, and quinolone antibiotics on bacterial extracellular vesicle release from .
临床相关的β-内酰胺类、氨基糖苷类和喹诺酮类抗生素对细菌细胞外囊泡释放的影响 (原文最后“from”后缺少内容)
bioRxiv. 2023 Nov 22:2023.11.22.568081. doi: 10.1101/2023.11.22.568081.
4
Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis.厄他培南治疗儿童感染的有效性:证据图谱与荟萃分析。
Front Pediatr. 2022 Oct 12;10:982179. doi: 10.3389/fped.2022.982179. eCollection 2022.
5
Antibacterial and Antibiofilm Potency of XF Drugs, Impact of Photodynamic Activation and Synergy With Antibiotics.XF 药物的抗菌和抗生物膜效力、光动力激活的影响以及与抗生素的协同作用。
Front Cell Infect Microbiol. 2022 Jun 30;12:904465. doi: 10.3389/fcimb.2022.904465. eCollection 2022.
6
Activity of Ertapenem against Neisseria gonorrhoeae Clinical Isolates with Decreased Susceptibility or Resistance to Extended-Spectrum Cephalosporins in Nanjing, China (2013 to 2019).厄他培南对中国南京对头孢菌素类药物耐药或敏感性降低的淋病奈瑟菌临床分离株的活性(2013 年至 2019 年)。
Antimicrob Agents Chemother. 2022 May 17;66(5):e0010922. doi: 10.1128/aac.00109-22. Epub 2022 May 2.
7
Carbapenem stewardship with ertapenem and antimicrobial resistance-a scoping review.碳青霉烯类药物管理与厄他培南和抗菌药物耐药性:范围综述。
Rev Soc Bras Med Trop. 2020 Nov 6;53:e20200413. doi: 10.1590/0037-8682-0413-2020. eCollection 2020.
8
Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against .贝那配南通过模型指导药物研发、药代动力学/药效学截断值确定及其对 的抗菌疗效
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01751-19.
9
In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii.新型抗菌组合对广泛耐药鲍曼不动杆菌的体外活性
Antimicrob Agents Chemother. 2015 Dec;59(12):7316-9. doi: 10.1128/AAC.00493-15. Epub 2015 Sep 14.
10
Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.出现了耐多药、广泛耐药和无法治疗的淋病。
Future Microbiol. 2012 Dec;7(12):1401-22. doi: 10.2217/fmb.12.117.